Life Sciences Tools & Diagnostics sector upgraded at Goldman

Goldman upgraded the Life Sciences Tools & Diagnostics sector to Attractive from Neutral. The firm does not believe investors are factoring in the impact of ACA and views pricing concerns as overdone. The firm reiterates its Buy on Quest Diagnostics (DGX), upgrades LabCorp (LH) to Neutral from Sell, downgraded Mettler-Toledo (MTD) to Neutal from Buy, and reiterates its Sell on Sigma-Aldrich (SIAL).